文献速递妇科

MEK抑制剂联合PI3K抑制剂对比MEK抑制剂单药治疗复发性低级别卵巢癌的II期随机双盲安慰剂对照试验

EMR 20006-012: A phase II randomized double-blind placebo controlled trial comparing the combination of pimasertib (MEK inhibitor) with SAR245409 (PI3K inhibitor) to pimasertib alone in patients with previously treated unresectable borderline or low grade ovarian cancer.
PubMed 文献 · Gynecol Oncol · 2019-12-20

本研究为II期随机双盲安慰剂对照试验,比较pimasertib(MEK抑制剂)联合SAR245409(PI3K抑制剂)与pimasertib单药在既往治疗过的不可切除交界性或低级别浆液性卵巢癌中的疗效。中位无进展生存期(PFS)单药组为7.23个月,联合组为9.99个月。因ORR低和中断率高,研究提前终止。

要点

  • 联合组ORR 9.4% vs 单药组12.1%,联合未优于单药。
  • 中位PFS单药组7.23个月 vs 联合组9.99个月。
  • 单药组ORR 12%提示MEK抑制可作为细胞毒化疗的替代选择。

核心结论

  • pimasertib单药在复发性LMP或LGSOC中显示一定疗效,ORR为12.1%,联合SAR245409未显示优效。
  • 因ORR低和中断率高,研究提前终止,需进一步研究MEK和PI3K抑制的单药或联合方案。

研究设计与样本

  • 患者随机接受pimasertib 60 mg每日联合SAR245409 70 mg每日,或pimasertib单药60 mg每日两次,直至进展或不可耐受毒性。

主要发现

  • 联合组ORR为9.4%(80% CI 3.5-19.7),单药组ORR为12.1%(80% CI 5.4-22.8)。
  • 中位PFS单药组为7.23个月(80% CI 5.06-未达到),联合组为9.99个月(80% CI 7.39-10.35)。
  • 6个月PFS率联合组为63.5%(80% CI 47.2%-75.9%),单药组为70.8%(80% CI 56.9%-80.9%)。

临床怎么用

  • pimasertib单药(ORR 12%)提示MEK抑制可作为该人群细胞毒化疗的替代治疗选择。
  • MEK抑制剂单药与联合方案疗效相当,但试验样本量小。

局限性

  • 原文述试验受样本量小限制。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To compare the combination of a MEK inhibitor (pimasertib) and a PI3K inhibitor (SAR245409) to pimasertib alone in recurrent unresectable borderline/low malignant potential (LMP) or low-grade serous ovarian carcinoma (LGSOC), determining whether combination is superior. METHODS: Patients with previously treated, recurrent LMP or LGSOC with measurable disease received either combination of pimasertib (60 mg daily) + SAR245409 (SAR) (70 mg daily) or pimasertib alone (60 mg BID) until progression or unacceptable toxicity. Primary endpoint was objective response rate (ORR) by RECIST 1.1, determining whether combination was superior to pimasertib alone. Secondary endpoints included progression free survival (PFS), disease control, and adverse events. RESULTS: Sixty-five patients were randomized between September 2012 and December 2014. ORR was 9.4% (80% CI, 3.5 to 19.7) in the combination arm and 12.1% (80% CI, 5.4 to 22.8) in the pimasertib alone arm. Median PFS was 7.23 months (80% CI, 5.06 to -) and 9.99 (80% CI, 7.39 to 10.35) for pimasertib alone and pimasertib + SAR, respectively. Six-month PFS was 63.5% (80% CI, 47.2% to 75.9%) and 70.8% (80% CI, 56.9% to 80.9%). Eighteen (56.3%) patients in the combination arm and 19 (57.6%) patients in the pimasertib alone arm discontinued the trial. The study was terminated early because of low ORR and high rate of discontinuation. CONCLUSIONS: Response to pimasertib alone (ORR 12%) suggests that MEK inhibition could be used as an alternative treatment method to cytotoxic chemotherapy in this population. The MEK inhibitor alone was as effective as the combination, although the trial was limited by small numbers. Additional studies investigating the role of single agent or combination MEK and PI3K inhibition are warranted to further evaluate the utility of these treatments and describe a standard of care for LGSOC.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Arend RC, Davis AM, Chimiczewski P, et al. EMR 20006-012: A phase II randomized double-blind placebo controlled trial comparing the combination of pimasertib (MEK inhibitor) with SAR245409 (PI3K inhibitor) to pimasertib alone in patients with previously treated unresectable borderline or low grade ovarian cancer. Gynecol Oncol. 2019. PMID: 31870556. doi:10.1016/j.ygyno.2019.12.002

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。